富含甲素的血小板驱动胰腺腺癌中的亲瘤性计划
Jonathan Gonzalez-Ruiz1,2, Miryam Sarmiento-Casas2, Ivan Bahena-Ocampo1
1Department of Ciencias de la Salud, Universidad Autónoma Metropolitana-Iztapalapa, Mexico City 09310, Mexico.
International journal of molecular sciences
|November 27, 2025
概括
血小板含有α-defensins (DEFA1/3),促进胰腺癌 (PDAC) 的生长和扩散. 针对这些血小板分子可能为攻击性PDAC提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 分子生物学分子生物学
背景情况:
- 胰腺管腺癌 (PDAC) 是一种致命的癌症,治疗选择有限.
- 血小板,除了静血,积极影响瘤的进展,并作为潜在的生物标志物.
- 血小板α-defensins (DEFA1/3) 在PDAC病原发生中的作用在很大程度上是未知的.
研究的目的:
- 研究DEFA1/3对PDAC进展的影响.
- 探索DEFA1/3在血小板和瘤细胞相互作用中的功能作用.
- 确定DEFA1/3作为PDAC中的潜在生物标志物和治疗点.
主要方法:
- 血小板转录组的生物信息分析.
- 使用胰腺癌细胞进行体外功能测试.
- 在体内斑马鱼异种移植模型以评估瘤扩散.
- 癌症基因组图谱 (TCGA) -PDAC临床数据的分析.
主要成果:
- 在PDAC衍生的血小板中,DEFA1/3的表达显著上调.
- 素丰富的血小板状颗粒 (DRP) 和重组DEFA1/3在体外增加了癌细胞的增殖,迁移和3D生长.
- DEFA1/3促进了斑马鱼异种移植中的瘤传播.
- 在PDAC患者中,高DEFA1/3表达与生存率差,免疫透率增加和EMT激活相关.
结论:
- 血小板衍生的DEFA1/3功能性调节PDAC进展.
- DEFA1/3将血小板颗粒含量与瘤的攻击性联系起来.
- 在PDAC的血小板-瘤轴上,DEFA1/3代表了一个潜在的生物标志物和治疗标.
相关概念视频
01:17Intracellular Signaling Affects Focal Adhesions
3.4K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
3.4K
01:35Cancer Cell Migration through Invadopodia
3.2K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K